Viewpoint: Knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization

Journal of Crohn's and Colitis

Volumn 8, Issue 11, 2014, Pages 1548-1550

  Danese, Silvio ^a   Fiorino, Gionata ^a   Michetti, Pierre ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b IBD Center Gastroenterology La Source Beaulieu ^*  (Switzerland)

Author keywords

Biosimilar; ECCO; Inflammatory bowel disease; Monoclonal

Indexed keywords

BIOSIMILAR AGENT; MONOCLONAL ANTIBODY; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; AWARENESS; DESCRIPTIVE RESEARCH; E-MAIL; HEALTH CARE ORGANIZATION; HEALTH SURVEY; HUMAN; INFLAMMATORY BOWEL DISEASE; KNOWLEDGE; MEDICAL SPECIALIST; MULTIPLE CHOICE TEST; PRIORITY JOURNAL; ATTITUDE TO HEALTH; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG APPROVAL; DRUG SUBSTITUTION; EUROPE; GASTROENTEROLOGY; HEALTH CARE SURVEY; HEALTH PERSONNEL ATTITUDE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ATTITUDE OF HEALTH PERSONNEL; BIOSIMILAR PHARMACEUTICALS; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG APPROVAL; DRUG SUBSTITUTION; EUROPE; GASTROENTEROLOGY; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS;

EID: 84929610400     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2014.06.007     Document Type: Article

References (5)

1. European Medicines Agency Inflectra 2013.
2. European Medicines Agency Remsima 2013.
3. Danese S., Gomollon F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis 2013, 7:586-589.
4. Park W., Hrycaj P., Jeka S., Kovalenko V., Lysenko G., Miranda P., et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013, 72:1605-1612.
5. Yoo D.H., Hrycaj P., Miranda P., Ramiterre E., Piotrowski M., Shevchuk S., et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013, 72:1613-1620.